SLG
AZN icon

Stanley-Laman Group’s AstraZeneca AZN Stock Holding History

Stanley-Laman Group’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.47M Sell
23,593
-457
-2% -$86K 0.45% 73
2026
Q1 		$4.74M Sell
24,050
-1,006
-4% -$194K 0.58% 60
2025
Q4 		$4.61M Buy
25,056
+898
+4% +$157K 0.59% 53
2025
Q3 		$3.71M Sell
24,158
-1,344
-5% -$203K 0.53% 74
2025
Q2 		$3.56M Sell
25,502
-3,923
-13% -$550K 0.53% 83
2025
Q1 		$4.33M Buy
29,425
+4,807
+20% +$695K 0.67% 51
2024
Q4 		$3.23M Sell
24,618
-7,628
-24% -$1.07M 0.45% 98
2024
Q3 		$5.02M Buy
32,246
+1,081
+3% +$174K 0.71% 42
2024
Q2 		$4.86M Buy
31,165
+1,338
+4% +$201K 0.7% 43
2024
Q1 		$4.04M Buy
29,827
+212
+0.7% +$28.1K 0.57% 76
2023
Q4 		$3.99M Buy
29,615
+3,139
+12% +$408K 0.61% 53
2023
Q3 		$3.59M Buy
+26,476
New +$3.62M 0.61% 61
2017
Q2 		– Sell
-38,641
Closed -$2.41M – 201
2017
Q1 		$2.41M Buy
38,641
+12,197
+46% +$710K 0.65% 49
2016
Q4 		$1.45M Buy
26,444
+2,970
+13% +$169K 0.45% 77
2016
Q3 		$1.54M Sell
23,474
-203
-0.9% -$13.3K 0.63% 33
2016
Q2 		$1.43M Buy
23,677
+9,418
+66% +$547K 0.56% 43
2016
Q1 		$803K Sell
14,259
-28,429
-67% -$1.71M 0.15% 138
2015
Q4 		$2.9M Sell
42,688
-20,681
-33% -$1.36M 0.5% 64
2015
Q3 		$4.03M Sell
63,369
-4,745
-7% -$312K 0.82% 36
2015
Q2 		$4.34M Buy
68,114
+43
+0.1% +$2.94K 0.8% 38
2015
Q1 		$4.66M Sell
68,071
-965
-1% -$67.1K 0.85% 39
2014
Q4 		$4.86M Sell
69,036
-3,978
-5% -$285K 0.92% 32
2014
Q3 		$5.22M Sell
73,014
-341
-0.5% -$25K 1.01% 28
2014
Q2 		$5.45M Buy
73,355
+288
+0.4% +$20.8K 1% 29
2014
Q1 		$4.74M Buy
73,067
+1,182
+2% +$76.3K 0.83% 39
2013
Q4 		$4.27M Buy
+71,885
New +$3.91M 0.93% 35

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Stanley-Laman Group's AZN Position: Q2 2026 in Review

Stanley-Laman Group reduced its AstraZeneca (AZN) stake by 1.9% in Q2 2026, selling an estimated $86K and leaving 23,593 shares worth $4.47M. The position accounts for 0.45% of the portfolio, ranked #73.

Stanley-Laman Group first reported a position in AZN in Q4 2013 and has held it in 26 quarters since. The position peaked at $5.45M in Q2 2014. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Stanley-Laman Group held 23,593 shares of AstraZeneca worth $4.47M as of Q2 2026.
  • Stanley-Laman Group sold 457 AstraZeneca shares in Q2 2026, an estimated $86K.
  • AstraZeneca made up 0.45% of Stanley-Laman Group's portfolio in Q2 2026, its #73 holding.
  • Stanley-Laman Group first reported a position in AstraZeneca in Q4 2013 and has held it in 26 quarters since.
  • Stanley-Laman Group's AstraZeneca position peaked at $5.45M in Q2 2014.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Stanley-Laman Group's 13F filing for Q2 2026, filed 5 Aug 2026.